NFKB1 and inflammatory bowel disease: While at the same time, many studies also demonstrated that NLRP3 inflammasome-mediated IL-1βand IL-18 release were involved in experimental colitis [11–14], suggesting that both NF-κB and NLRP3 axis may serve as potential targets for the development of novel therapeutics for patients with inflammatory bowel diseases.